BioSpace News Archive

Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies.

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Wednesday, November 8, 2023 after market close and will host a conference call that same day at 4:30pm ET.

Altimmune, Inc. today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023). Diseases (AA

Curium, a world leader in nuclear medicine, and PIUR IMAGING announced today a strategic partnership to advance thyroid diagnostics in Germany.

Merck and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA with respective clinical criteria and conditions for adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell carcinoma (RCC), with no prior systemic therapy for metastatic RCC.

Hummingbird Diagnostics GmbH today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.

Cybin Inc. today announced that the United States Patent and Trademark Office has issued two patent grants that offer protection for its deuterated N, N-dimethyltryptamine (“DMT”) program.

Sonnet BioTherapeutics Holdings, Inc. today announced the pricing of an underwritten public offering of 2,843,750 shares of common stock (or pre-funded warrants to purchase shares of common stock.

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it will be unveiling the new brand for its coactiv+™ Antimicrobial Wound Gel product (“Wound Gel”) at the Symposium on Advanced Wound Care Fall forum (“SAWC Fall”).

CANbridge Pharmaceuticals, Inc. today announced that data from the preclinical evaluation of CAN201, a potential gene therapy for Fabry disease, will be presented at the at the European Society Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place from October 24-27 in Brussels, Belgium.